Why Hims & Hers Health Stock Sank This Week
Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its ...
Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Why Hims & Hers Stock Rebounded on Wednesday
Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...
Hims & Hers price target raised to $44 from $28 at TD Cowen
TD Cowen raised the firm’s price target on Hims & Hers to $44 from $28 and keeps a Buy rating on the shares. The firm continues to believe ...
Hims & Hers: Brace For Impact As It Faces A Possible 18% Revenue Hit
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Modern Healthcare4d
Hims & Hers pivots as semaglutide shortage ends
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...